MAGEA4 is an interesting candidate for targeted immunotherapy, and recently a MAGEA4‐reactive, HLA‐A2‐restricted T‐cell receptor was engineered, showing effectivity and safety in either CD4 or CD8 preclinical assays, suggesting a clinical strategy for an agnostic treatment of MAGE4 positive cancer [52]. Here, CD8A is linked to cancer.